Tags

Type your tag names separated by a space and hit enter

Pharmacologic therapy for urticaria.
Allergol Immunopathol (Madr). 1997 Jan-Feb; 25(1):36-51.AI

Abstract

Treatment of chronic urticaria presents a challenge to both practitioner and patient. Traditional H1 antagonists with good efficacy but substantial side effects are being supplanted in many cases by nonsedating H1. Combinations of H1 and H2 antagonists offer improved results for selected patients. Second-line therapies include a wide range of drugs such as doxepin, dapsone, attenuated androgens, calcium antagonists, antimalarials, gold and methotrexate. The most effective and regularly used second-line agents are corticosteroids. These are best limited to short term crisis management, except in severe recalcitrant cases, and in patients with pressure urticaria or urticarial vasculitis. Further development and investigation of mast cell stabilisers and inhibitors of urticaria mediators other than histamine hold promise. A better understanding of the underlying pathogenesis remains the greatest hope of formulating rational and effective therapy.

Authors+Show Affiliations

Allergology Section, H. U. Virgen de la Arrixaca El Palmar, Murcia, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9111875

Citation

Negro-Alvarez, J M., et al. "Pharmacologic Therapy for Urticaria." Allergologia Et Immunopathologia, vol. 25, no. 1, 1997, pp. 36-51.
Negro-Alvarez JM, Carreño-Rojo A, Funes-Vera E, et al. Pharmacologic therapy for urticaria. Allergol Immunopathol (Madr). 1997;25(1):36-51.
Negro-Alvarez, J. M., Carreño-Rojo, A., Funes-Vera, E., García-Cánovas, A., Abellán-Alemán, A. F., & Rubio del Barrio, R. (1997). Pharmacologic therapy for urticaria. Allergologia Et Immunopathologia, 25(1), 36-51.
Negro-Alvarez JM, et al. Pharmacologic Therapy for Urticaria. Allergol Immunopathol (Madr). 1997 Jan-Feb;25(1):36-51. PubMed PMID: 9111875.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologic therapy for urticaria. AU - Negro-Alvarez,J M, AU - Carreño-Rojo,A, AU - Funes-Vera,E, AU - García-Cánovas,A, AU - Abellán-Alemán,A F, AU - Rubio del Barrio,R, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 36 EP - 51 JF - Allergologia et immunopathologia JO - Allergol Immunopathol (Madr) VL - 25 IS - 1 N2 - Treatment of chronic urticaria presents a challenge to both practitioner and patient. Traditional H1 antagonists with good efficacy but substantial side effects are being supplanted in many cases by nonsedating H1. Combinations of H1 and H2 antagonists offer improved results for selected patients. Second-line therapies include a wide range of drugs such as doxepin, dapsone, attenuated androgens, calcium antagonists, antimalarials, gold and methotrexate. The most effective and regularly used second-line agents are corticosteroids. These are best limited to short term crisis management, except in severe recalcitrant cases, and in patients with pressure urticaria or urticarial vasculitis. Further development and investigation of mast cell stabilisers and inhibitors of urticaria mediators other than histamine hold promise. A better understanding of the underlying pathogenesis remains the greatest hope of formulating rational and effective therapy. SN - 0301-0546 UR - https://www.unboundmedicine.com/medline/citation/9111875/Pharmacologic_therapy_for_urticaria_ L2 - https://medlineplus.gov/hives.html DB - PRIME DP - Unbound Medicine ER -